T1	Participants 89 137	patients with hormone-refractory prostate cancer
T2	Participants 346 357	multicenter
T3	Participants 403 415	380 patients
T4	Participants 433 446	men with HRPC
T5	Participants 218 259	hormone-refractory prostate cancer (HRPC)
T6	Participants 448 544	After 50 randomized patients, the trial was closed to further accrual by the sponsoring company.
T7	Participants 604 788	Eligibility criteria included pathological proof of prostate cancer, documented progression despite prior hormonal manipulation, WHO PS 0-2, and no daily intake of narcotic analgesics.
